Senti Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Emily Bodnar from H.C. Wainwright maintained a Buy rating on the stock and has a $12.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on the promising clinical data and safety profile of Senti Biosciences’ SENTI-202 therapy. The company recently reported encouraging results from its Phase 1 trial for relapsed/refractory acute myeloid leukemia (AML), where SENTI-202 demonstrated a favorable safety profile with no dose-limiting toxicities and a manageable adverse event profile.
The observed overall response rate and complete response rates, despite being from a small patient cohort, suggest potential efficacy of the therapy. The anticipation of further data at the upcoming ASH conference, which could provide additional insights into response rates, durability, and safety, supports the positive outlook. The innovative CAR-NK technology, which targets specific leukemic cells while sparing healthy cells, adds to the potential of SENTI-202 as a promising treatment option, justifying the Buy rating.
In another report released yesterday, Chardan Capital also maintained a Buy rating on the stock with a $12.00 price target.